Location & dates EMBL Heidelberg, Germany 5 - 7 Feb 2020
Deadlines Registration closed Abstract submission closed

EMBL Courses and Conferences during the Coronavirus pandemic

With the onsite programme paused, many of our events are now being offered in virtual formats.


Registration is open as usual for many events, with back-up plans in place to move further courses and conferences online as necessary. Registration fees for any events affected by the COVID-19 disruption are fully refundable.


More information for participants of events at EMBL Heidelberg can be found here.

Programme

Got something to say? Tweet it! #EMBLProteome 

Day 1 - Wednesday 05 February 2020
TimeSpeaker
11:00-13:00 Arrival and Registration 
with light refreshments

11:45-12:45

Pre-conference workshop
13:00-13:30 Opening talk
The challenge of expanding the druggable proteome
Adrian Carter, Boehringer Ingelheim, Germany
13:30-15:00

Session 1: Illuminating the challenge and highlighting the opportunity for creating new medicines
Chair: Adrian Carter

13:30-14:00

Illuminating the Druggable Genome with Informatics, Data Science and Machine Learning 
Tudor Oprea - University of New Mexico, USA

14:00-14:30

Functionalization of the human protein-coding genome to discover medicines for neurodegenerative disease
Heiko Runz - Biogen, USA

14:30-15:00

Chemical probes and the chemical biology of cancer
Paul Workman - CRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK

15:00-15:30

Coffee break

15:30-17:45

Session 2: Illuminating the most promising proteins by virtue of druggability, human genetics and bioinformatics
Chair: Patrick Aloy

15:30-16:00

Computational identification of drug targets in cancer
Eytan Ruppin - National Cancer Institute, USA

16:00-16:15

Proteome-wide identification of new druggable targets for antibiotics
Stephan Hacker - Technical University of Munich, Germany

16:15-16:45

Target Tractability: Making full use of protein homology
Kristin Brown - GlaxoSmithKline, UK

16:45-17:15

Epigenetic variation across individuals to understand disease mechanisms
Judith Zaugg - EMBL Heidelberg, Germany

17:15-17:45

Extending the small molecule similarity principle to all levels of biology 
Patrick Aloy - IRB Barcelona, Spain

17:45-18:35

Poster Session 1 (odd numbers)
with beer and snacks, ATC Helix A

18:35-19:30

Poster Session 2  (even numbers)
with beer and snacks, ATC Helix A

19:30-20:45

Dinner
EMBL Canteen

20:45-22:00 After Dinner Drinks
ATC Rooftop Lounge
20:00, 21:00, 22:00  Bus departure
Day 2 - Thursday 06 February 2020
TimeSpeaker
09:00-12:30

Session 3: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 1
Chair: Gerard Drewes

09:00-09:30

Shaping biology by modulating access to chemical matter
Giulio Superti-Furga - CeMM Research Centre for Molecular Medicine/ Medical University of Vienna, Austria

09:30-09:45

The target landscape of 1,200 kinase inhibitors
Maria Reinecke - Technical University of Munich/ DKTK partner site Munich, Germany

09:45-10:00

Covalent inhibitors for 'undruggable' targets
Nir London - The Weizman Institute of Science, Israel

10:00-10:30

Targeting protein scaffolding function in kinases
Stefan Knapp - Goethe University Frankfurt, Germany

10:30-11:00

Coffee break

11:00-11:30

Exploring the druggable proteome by image-based phenotyping in cell lines and patient derived organoids 
Michael Boutros - German Cancer Research Centre/ Heidelberg University, Germany

11:30-12:00

Mechanisms of intracellular DNA sensing through the cGAS-STING pathway
Andrea Ablasser - EPFL, Switzerland

12:00-12:15

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Georg Petzold - Friedrich Miescher Institute for Biomedical Research, Switzerland

12:15-12:30

Stabilization of protein-protein interactions
Pim de Vink - Eindhoven University of Technology, The Netherlands

12:30-14:00

Lunch and meet the speakers

14:00-16:00

Session 4: Interrogating the druggable proteome with chemical probes, imaging and sensor proteins, part 2
Chair: Anke Müller-Fahrnow

14:00-14:30

Tetrahydrobiopterin homeostasis
Kai Johnsson - Max Planck Institute for Medical Research, Germany 

14:30-15:00

Chemical physiology of natural products and antibody conjugates
Gonçalo Bernardes - University of Cambridge, UK and iMM Lisboa, Portugal

15:00-15:30

Within our control? Leveraging precision electrophile signaling toward drug discovery
Yimon Aye - EPFL, Switzerland

15:30-16:00

Understanding cellular phenotypes; from screens to probes towards clinical candidates
Marcus Bauser - Bayer AG, Germany

16:00-16:30

Coffee break

16:30-19:00 Session 5: Interrogating the druggable proteome with phenotypic screens
Chair: Herbert Waldmann 
16:30-16:45 Towards improved biophysical models of protein folding to identify disease-causing mutations and rescue by small molecules
Amelie Stein - University of Copenhagen, Denmark
16:45-17:00 Using metabolic fingerprints to rationally design combination therapies
Mattia Zampieri - ETH Zürich, Switzerland
17:00-17:30 Pseudo Natural Products 
Herbert Waldmann - Max Planck Institute of Molecular Physiology, Germany
17:30-18:00

A systems approach to functional precision medicine by deep learning and multi-OMICs
Berend Snijder - ETH Zürich, Switzerland

18:00-18:30 Advances in phenotypic and pathway profiling: Elucidating novel target biology and drug mechanism-of-action under appropriate biological context 
Neil Carragher - The University of Edinburgh, UK
18:45-20:30 Conference Dinner
EMBL Canteen
20:30-23:00 After Dinner Drinks, live music
ATC Rooftop Lounge
20:00, 21:30, 23:00 Bus departure
Day 3 - Friday 07 February 2020
TimeSpeaker
09:00-10:45 Session 6: New engineering approaches for expanding the druggable proteome
Chair: Stefan Knapp
09:00-09:30

Mapping genetic networks using functional and chemical genomics
Brenda Andrews - University of Toronto, Canada

09:30-10:00

Biophysical screening of combinatorial libraries to target protein-protein interactions with covalent agents
Maurizio Pellecchia - University of California, Riverside, USA

10:00-10:15

NanoBRET cellular target engagement assays are versatile in enabling drug screening for various proteins – the SGC experience
Benedict Berger - Structural Genomics Consortium, Goethe University Frankfurt, Germany

10:15-10:45

Chemical biology at the interface of discovery to deliver novel to targets to the Drug Discovery Pipeline
Christine Donahue - GlaxoSmithKline, USA

10:45-11:15

Coffee break

11:15-13:15

Session 7: New engineering approaches for breaking the druggability barrier
Chair: Katrin Rittinger

11:15-11:45

Targeting the active site of E3 ligases with chemical tools
Katrin Rittinger - The Francis Crick Institute, UK

11:45-12:15

Structure based PROTAC design to expand the druggable proteome
Alessio Ciulli - University of Dundee, UK

12:15-12:45

Chemical probes in target discovery
Paul Brennan - University of Oxford, UK

12:45-13:15

Identification of microbiome-encoded enzymes involved in drug metabolism
Michael Zimmermann - EMBL Heidelberg, Germany

13:15-13:30 Closing remarks and Poster Prize
13:30-14:00

End of conference
Packed lunch and departure

14:00

Bus departure all stops downtown

14:10

Bus to Frankfurt Intl. Airport